Wayfinding Financial, LLC Bristol Myers Squibb CO Transaction History

Wayfinding Financial, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 29, 2025	BUY	$53.9 - $63.11 $182,343 - $213,501	3,383 New	3,383 $206,000
Q4 2023 Jan 09, 2024	BUY	$48.48 - $57.85 $8,726 - $10,413	180 Added 4.03%	4,642 $238,000
Q3 2023 Nov 02, 2023	SELL	$57.89 - $64.73 $16,903 - $18,901	-292 Reduced 6.14%	4,462 $258,000
Q2 2023 Jul 31, 2023	BUY	$63.71 - $70.74 $13,124 - $14,572	206 Added 4.53%	4,754 $304,000
Q1 2023 May 04, 2023	BUY	$65.71 - $74.53 $68,404 - $77,585	1,041 Added 29.68%	4,548 $315,000
Q4 2022 Feb 09, 2023	SELL	$68.48 - $81.09 $28,967 - $34,301	-423 Reduced 10.76%	3,507 $223,000
Q3 2022 Nov 08, 2022	BUY	$0.13 - $76.84 $3 - $2,228	29 Added 0.74%	3,930 $279,000
Q2 2022 Aug 09, 2022	SELL	$72.62 - $79.98 $1,525 - $1,679	-21 Reduced 0.54%	3,901 $302,000
Q1 2022 May 09, 2022	BUY	$61.48 - $73.72 $25,514 - $30,593	415 Added 11.83%	3,922 $300,000
Q4 2021 Jan 28, 2022	BUY	$53.63 - $62.52 $188,080 - $219,257	3,507 New	3,507 $223,000

2,668

1.58B

26.1M

23.8M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $97.7B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Wayfinding Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Wayfinding Financial, LLC with notifications on news.